Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
Imatinib is approved as the first-line treatment for newly diagnosed chronic myelogenous leukemia (CML). In spite of profound response in the majority of patients, resistance occurs in a subgroup of CML cases. Recently, it has been demonstrated that different classes of non-coding RNAs can modulate...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2025-01-01
|
| Sarja: | Leukemia Research Reports |
| Aiheet: | |
| Linkit: | http://www.sciencedirect.com/science/article/pii/S2213048925000317 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|